<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Biopharma News Feed - Ophthalmology</title><link>https://nrouizem.github.io/test/ophthalmology_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/ophthalmology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Sat, 08 Mar 2025 01:06:22 +0000</lastBuildDate><item><title>FDA approves Neurotech therapy for rare eye disease</title><link>https://endpts.com/fda-approves-neurotech-therapy-for-rare-eye-disease/</link><description>The FDA approved Neurotech Pharmaceuticals' cell therapy for macular telangiectasia type 2, marking the first treatment for the progressive eye disease that distorts central vision. The therapy involves implanting a cell-containing device to slow vision loss, with the company planning to make it available in the second half of 2024.</description><pubDate>Fri, 07 Mar 2025 19:57:13 +0000</pubDate></item></channel></rss>
